Flash Finance

Pharmaceuticals: Q1 FY27 results (April-June 2026)

106 companies have declared Pharmaceuticals Q1 FY27 results so far, the latest on 21 Sep 2026.

Across the 99 non-financial companies with a year-ago quarter to compare, sales grew +13.6% and net profit +7.6% year on year, and the combined operating margin narrowed 144 bps to 21.6%.

68% of companies grew net profit; 5 turned a loss into a profit; 47% beat their own profit trend and 40% fell short of it.

Updated 12 Oct 2026, 13:17 IST 106 declared 112 due in the next 3 days →

Pharmaceuticals Q1 FY27 scoreboard

Sales growth
+13.6%
YoY, 99 companies combined; median +17.0%
Net profit growth
+7.6%
YoY combined; median +26.1%
Operating margin
21.6%
-144 bps YoY
Grew profit
68%
5 turnarounds, 4 into loss
Vs own profit trend
47% / 40%
above / below, 13% in line
Price since results
-2.1%
median; 46% of 98 stocks up
Other-income heavy
24
25%+ of pre-tax profit from other income & one-offs

Latest Pharmaceuticals Q1 FY27 results 106

Page 4 of 4

Sakar Healthcare Limited

SAKAR · Pharmaceuticals · Q1 FY27 · Standalone · Filed
M Cap
₹2,220 Cr
P/E
61.5
PEG
1.81
Since results
+18.9%
  • Profit +17% above its own trend
  • Operating margin expanded 503 bps YoY
  • Core business grew faster than reported profit (core profit +161%)
₹ CrYoYQoQ Jun 2026Mar 2026Jun 2025
Sales +38.4%+2.6% 73.071.152.7
Operating profit +67.2%-19.0% 21.226.212.7
OPM % +503 bps-778 bps 29.1%36.9%24.1%
Other income +292.0%+801.8% 1.50.20.4
Net profit +120.2%-6.7% 10.311.04.7
PAT margin % +524 bps-141 bps 14.1%15.5%8.9%
EPS (₹) +119.0%-6.9% 4.624.962.11

Quality of profit

Core 89%Other income & one-offs 11%

Pre-tax profit ₹14.6 Cr: core business ₹13.0 Cr, other income ₹1.5 Cr.

Core profit YoY: +161.2% · reported profit +120.2%

Cash & debt

FY26 cash from operations ₹49.0 Cr: 161% of FY26 net profit of ₹30.5 Cr.

Borrowings ₹55.0 Cr at Mar 2026.

Against its own trend ?

TrendActualGap
Sales₹73.0₹73.0 -0.0% in line
Net profit₹8.8₹10.3 +16.7% above
AI read of the filing Sakar Healthcare Q1 FY27: Net Profit Jumps 120% YoY to ₹10.28 Cr Positive
  • Revenue from operations increased 38.3% YoY to ₹72.97 Cr from ₹52.74 Cr.
  • Net profit grew 120% YoY to ₹10.28 Cr from ₹4.67 Cr in the same quarter last year.
  • Earnings Per Share (EPS) rose to ₹4.62 compared to ₹2.11 in Q1 FY26.
Full analysis →
📊 Investor presentation (28 Jul) 📄 Results filing (PDF) Detailed financials →

Solara Active Pharma Sciences Limited

SOLARA · Pharmaceuticals · Q1 FY27 · Consolidated · Filed
M Cap
₹3,109 Cr
P/E
—
PEG
—
Since results
+24.1%
  • Operating margin contracted 163 bps YoY
₹ CrYoYQoQ Jun 2026Mar 2026Jun 2025
Sales +19.6%-1.5% 382387319
Operating profit +8.7%+7.5% 62.057.757.0
OPM % -163 bps+135 bps 16.2%14.9%17.9%
Other income +174.5%-51.5% 2.75.51.0
Net profit +55.0%+69.9% 16.39.610.5
PAT margin % +98 bps+180 bps 4.3%2.5%3.3%
EPS (₹) +43.1%+32.8% 3.522.652.46

Quality of profit

Core 84%Other income & one-offs 16%

Pre-tax profit ₹16.3 Cr: core business ₹13.6 Cr, other income ₹2.7 Cr.

Core profit YoY: +42.8% · reported profit +55.0%

Cash & debt

FY26 cash from operations ₹153 Cr.

Borrowings ₹687 Cr at Mar 2026.

Against its own trend ?

TrendActualGap
Sales₹330₹382 +15.8% above
AI read of the filing Solara Board Approves Q1 FY27 Results; Targets Quarterly Revenue of ₹350 Cr+ Neutral
  • Board meeting held on July 23, 2026, concluded within 65 minutes (12:00 PM to 1:05 PM).
  • Company is targeting a quarterly revenue run-rate of ₹350 Cr+ to sustain its growth strategy.
  • TTM revenue stands at ₹1,369 Cr against a total debt of ₹637 Cr.
Full analysis →
📄 Results filing (PDF) Detailed financials →

Cipla Limited

CIPLA · Pharmaceuticals · Q1 FY27 · Consolidated · Filed
M Cap
₹1,05,102 Cr
P/E
31.3
PEG
3.13
Since results
-7.9%
  • Profit -18% below its own trend
  • Operating margin contracted 881 bps YoY
₹ CrYoYQoQ Jun 2026Mar 2026Jun 2025
Sales +2.3%+8.8% 7,1196,5416,957
Operating profit -32.9%+24.8% 1,1929551,778
OPM % -881 bps+215 bps 16.7%14.6%25.6%
Other income -18.4%+42.5% 211148259
Net profit -39.2%+44.7% 7865431,292
PAT margin % -753 bps+273 bps 11.0%8.3%18.6%
EPS (₹) -39.2%+42.2% 9.776.8716.07

Quality of profit

Core 80%Other income & one-offs 20%

Pre-tax profit ₹1,082 Cr: core business ₹871 Cr, other income ₹211 Cr.

Core profit YoY: -42.4% · reported profit -39.2%

Cash & debt

FY26 cash from operations ₹3,940 Cr: 102% of FY26 net profit of ₹3,862 Cr.

Borrowings ₹614 Cr at Mar 2026.

Against its own trend ?

TrendActualGap
Sales₹7,095₹7,119 +0.3% in line
Net profit₹959₹786 -18.0% below
AI read of the filing Cipla Q1 FY27: Net Profit drops 39% YoY to ₹786 Cr; Revenue grows 2.3% to ₹7,119 Cr Negative
  • Consolidated Revenue from operations stood at ₹7,119.28 Cr, up 2.3% YoY from ₹6,957.47 Cr.
  • Net Profit for the quarter fell to ₹785.55 Cr, a 39.2% decrease compared to ₹1,291.61 Cr in Q1 FY26.
  • Employee benefit expenses increased by 14.1% YoY to ₹1,497.41 Cr from ₹1,312.30 Cr.
Full analysis →
📊 Investor presentation (23 Jul) 📄 Results filing (PDF) Detailed financials →

Dr. Reddy's Laboratories Limited

DRREDDY · Pharmaceuticals · Q1 FY27 · Consolidated · Filed
M Cap
₹99,709 Cr
P/E
30.5
PEG
—
Since results
+4.0%
  • Profit -67% below its own trend
  • Operating margin contracted 1576 bps YoY
  • 54% of pre-tax profit came from other income and one-off items
₹ CrYoYQoQ Jun 2026Mar 2026Jun 2025
Sales -5.6%+7.0% 8,0707,5468,545
Operating profit -78.3%-0.9% 3783821,748
OPM % -1576 bps-37 bps 4.7%5.1%20.5%
Other income +24.8%-37.6% 300480240
Net profit -69.2%+96.7% 4352211,410
PAT margin % -1111 bps+246 bps 5.4%2.9%16.5%
EPS (₹) -68.8%+100.8% 5.322.6517.04

Quality of profit

Core 46%Other income & one-offs 54%

Pre-tax profit ₹553 Cr: core business ₹253 Cr, other income ₹300 Cr.

Core profit YoY: -78.7% · reported profit -69.2%

Cash & debt

FY26 cash from operations ₹5,674 Cr: 134% of FY26 net profit of ₹4,247 Cr.

Borrowings ₹7,734 Cr at Mar 2026.

Against its own trend ?

TrendActualGap
Sales₹8,483₹8,070 -4.9% in line
Net profit₹1,311₹435 -66.8% below
AI read of the filing Dr. Reddy's Q1 PAT Drops 69% to ₹434.8 Cr; ₹239.7 Cr Provision for Semaglutide Quality Issue Negative
  • Consolidated Revenue declined 5.5% YoY to ₹8,070.5 Cr compared to ₹8,545.2 Cr in Q1 FY26.
  • Net Profit plummeted 69.1% YoY to ₹434.8 Cr, significantly lower than the ₹1,409.6 Cr reported in the previous year's quarter.
  • A one-time provision of ₹239.7 Cr was recorded due to quality issues in the API used for Semaglutide batches.
Full analysis →
📊 Investor presentation (22 Jul) 📄 Results filing (PDF) Detailed financials →

Granules India Limited

GRANULES · Pharmaceuticals · Q1 FY27 · Consolidated · Filed
M Cap
₹20,202 Cr
P/E
30.5
PEG
6.10
Since results
-7.1%
  • Profit +22% above its own trend
  • Operating margin expanded 254 bps YoY
₹ CrYoYQoQ Jun 2026Mar 2026Jun 2025
Sales +22.0%+0.4% 1,4771,4711,210
Operating profit +37.2%-3.7% 339352247
OPM % +254 bps-98 bps 22.9%23.9%20.4%
Other income from loss-90.9% 2.325.0-10.0
Net profit +59.3%-10.9% 180202113
PAT margin % +285 bps-155 bps 12.2%13.7%9.3%
EPS (₹) +56.5%-10.7% 7.268.134.64

Quality of profit

Core 99%Other income & one-offs 1%

Pre-tax profit ₹240 Cr: core business ₹238 Cr, other income ₹2.3 Cr.

Core profit YoY: +54.6% · reported profit +59.3%

Cash & debt

FY26 cash from operations ₹793 Cr: 133% of FY26 net profit of ₹596 Cr.

Borrowings ₹1,512 Cr at Mar 2026.

Against its own trend ?

TrendActualGap
Sales₹1,481₹1,477 -0.3% in line
Net profit₹147₹180 +22.3% above
📄 Results filing (PDF) Detailed financials →

Bajaj Healthcare Limited

BAJAJHCARE · Pharmaceuticals · Q1 FY27 · Consolidated · Filed
M Cap
₹1,077 Cr
P/E
—
PEG
—
Since results
-17.4%
₹ CrYoYQoQ Jun 2026Mar 2026Jun 2025
Sales +11.3%— 166—149
Operating profit +16.2%— 28.5—24.5
OPM % +73 bps— 17.2%—16.5%
Other income -7.6%— 0.8—0.9
Net profit +15.8%— 13.7—11.8
PAT margin % +32 bps— 8.3%—8.0%
EPS (₹) +8.8%— 4.07—3.74

Quality of profit

Core 95%Other income & one-offs 5%

Pre-tax profit ₹16.2 Cr: core business ₹15.4 Cr, other income ₹0.8 Cr.

Core profit YoY: +12.7% · reported profit +15.8%

AI read of the filing Q1 FY27 Net Profit Up 15.8% YoY to ₹13.70 Cr; Revenue Grows 11.3% Positive
  • Revenue from operations increased 11.3% YoY to ₹165.63 cr from ₹148.84 cr.
  • Net profit after tax rose 15.8% YoY to ₹13.70 cr compared to ₹11.83 cr in the previous year's quarter.
  • Utilized ₹150 cr for debt repayment out of the ₹204.97 cr raised through preferential issues.
Full analysis →
📄 Results filing (PDF) Detailed financials →

Venus Remedies Limited

VENUSREM · Pharmaceuticals · Q1 FY27 · Consolidated · Filed
M Cap
₹2,155 Cr
P/E
18.5
PEG
0.32
Since results
-4.9%
  • Profit +20% above its own trend
  • Operating margin expanded 1146 bps YoY
  • Core business grew faster than reported profit (core profit +601%)
₹ CrYoYQoQ Jun 2026Mar 2026Jun 2025
Sales +35.6%-30.9% 179259132
Operating profit +238.5%-45.7% 34.263.010.1
OPM % +1146 bps-521 bps 19.1%24.3%7.7%
Other income -69.9%-47.6% 2.65.08.7
Net profit +139.3%-52.1% 23.048.09.6
PAT margin % +556 bps-569 bps 12.8%18.5%7.3%
EPS (₹) +139.3%-51.7% 17.1835.547.18

Quality of profit

Core 91%Other income & one-offs 9%

Pre-tax profit ₹30.0 Cr: core business ₹27.4 Cr, other income ₹2.6 Cr.

Core profit YoY: +601.3% · reported profit +139.3%

Cash & debt

FY26 cash from operations ₹156 Cr: 151% of FY26 net profit of ₹103 Cr.

Borrowings ₹12.0 Cr at Mar 2026.

Against its own trend ?

TrendActualGap
Sales₹156₹179 +14.6% above
Net profit₹19.2₹23.0 +19.6% above
AI read of the filing Venus Remedies Q1 Net Profit Jumps 118% YoY to ₹25.53 Cr; Revenue Up 30% Positive
  • Standalone Revenue from Operations increased 30.4% YoY to ₹178.80 Cr from ₹137.13 Cr.
  • Net Profit grew by 118.2% YoY to ₹25.53 Cr compared to ₹11.70 Cr in the same quarter last year.
  • EBITDA rose 89.3% YoY to ₹39.11 Cr, reflecting improved manufacturing and administrative efficiencies.
Full analysis →
📄 Results filing (PDF) Detailed financials →

Beta Drugs Limited

BETA · Pharmaceuticals · Q1 FY27 · Consolidated · Filed
M Cap
₹1,969 Cr
P/E
34.4
PEG
3.12
Since results
-16.1%
₹ CrYoYQoQ Jun 2026Mar 2026Jun 2025
Sales —+33.6% 12694.0—
Operating profit —+54.8% 27.417.7—
OPM % —+298 bps 21.8%18.8%—
Other income —-45.2% 1.62.9—
Net profit —+74.6% 15.89.1—
PAT margin % —+295 bps 12.6%9.6%—
EPS (₹) —+65.5% 14.788.93—

Quality of profit

Core 93%Other income & one-offs 7%

Pre-tax profit ₹22.0 Cr: core business ₹20.5 Cr, other income ₹1.6 Cr.

Core profit YoY: —

Cash & debt

FY26 cash from operations ₹37.0 Cr.

Borrowings ₹148 Cr at Mar 2026.

AI read of the filing 40.9% PAT Growth in Q1FY27; Beta Drugs Reports Rs 125.55 Cr Sales and Margin Expansion Positive
  • Consolidated total sales reached Rs 125.55 Cr, a 25.3% increase from Rs 100.2 Cr in Q1FY26.
  • Net Profit grew 40.92% YoY to Rs 16.5 Cr, representing ~32% of the total TTM PAT.
  • Branded Oncology segment delivered 47% YoY growth, recording sales of Rs 33.0 Cr.
Full analysis →
📊 Investor presentation (27 Jul) 📄 Results filing (PDF) Detailed financials →

Abbott India Limited

ABBOTINDIA · Pharmaceuticals · Q1 FY27 · Standalone
M Cap
₹55,248 Cr
P/E
34.2
PEG
1.90
  • Operating margin expanded 311 bps YoY
₹ CrYoYQoQ Jun 2026Mar 2026Jun 2025
Sales +4.4%+6.1% 1,8141,7101,738
Operating profit +17.0%+8.5% 522481446
OPM % +311 bps+65 bps 28.8%28.1%25.7%
Other income +2.7%-1.3% 75.076.073.0
Net profit +17.2%+8.6% 429395366
PAT margin % +259 bps+55 bps 23.6%23.1%21.1%
EPS (₹) +17.1%+8.5% 201.66185.86172.18

Quality of profit

Core 87%Other income & one-offs 13%

Pre-tax profit ₹572 Cr: core business ₹496 Cr, other income ₹75.0 Cr, exceptional & other items ₹1.0 Cr.

Core profit YoY: +17.8% · reported profit +17.2%

Cash & debt

FY26 cash from operations ₹1,319 Cr: 85% of FY26 net profit of ₹1,552 Cr.

Borrowings ₹172 Cr at Mar 2026.

Against its own trend ?

TrendActualGap
Sales₹1,863₹1,814 -2.6% in line
Net profit₹401₹429 +6.9% in line
Detailed financials →

Pfizer Limited

PFIZER · Pharmaceuticals · Q1 FY27 · Standalone
M Cap
₹17,422 Cr
P/E
23.7
PEG
2.96
  • Operating margin expanded 315 bps YoY
₹ CrYoYQoQ Jun 2026Mar 2026Jun 2025
Sales +8.3%+3.8% 653629603
Operating profit +18.1%+5.1% 248236210
OPM % +315 bps+46 bps 38.0%37.5%34.8%
Other income -32.8%-10.0% 45.050.067.0
Net profit +6.2%+2.0% 204200192
PAT margin % -60 bps-56 bps 31.2%31.8%31.8%
EPS (₹) +6.7%+2.3% 44.7043.6841.91

Quality of profit

Core 84%Other income & one-offs 16%

Pre-tax profit ₹277 Cr: core business ₹233 Cr, other income ₹45.0 Cr, exceptional & other items −₹1.0 Cr.

Core profit YoY: +20.7% · reported profit +6.2%

Cash & debt

FY26 cash from operations ₹968 Cr: 134% of FY26 net profit of ₹723 Cr.

Borrowings ₹70.0 Cr at Mar 2026.

Against its own trend ?

TrendActualGap
Sales₹652₹653 +0.2% in line
Net profit₹222₹204 -8.0% in line
Detailed financials →

Novartis India

NOVARTIND · Pharmaceuticals · Q1 FY27 · Standalone
M Cap
₹5,059 Cr
P/E
52.1
PEG
—
  • Profit +18% above its own trend
  • Operating margin expanded 297 bps YoY
  • Core business grew faster than reported profit (core profit +35%)
₹ CrYoYQoQ Jun 2026Mar 2026Jun 2025
Sales +18.2%+14.3% 10491.088.0
Operating profit +29.6%+66.7% 35.021.027.0
OPM % +297 bps+1058 bps 33.7%23.1%30.7%
Other income -18.2%-10.0% 9.010.011.0
Net profit +14.3%+28.0% 32.025.028.0
PAT margin % -105 bps+330 bps 30.8%27.5%31.8%
EPS (₹) +16.6%+27.6% 13.0510.2311.19

Quality of profit

Core 81%Other income & one-offs 19%

Pre-tax profit ₹43.0 Cr: core business ₹35.0 Cr, other income ₹9.0 Cr, exceptional & other items −₹1.0 Cr.

Core profit YoY: +34.6% · reported profit +14.3%

Cash & debt

FY26 cash from operations ₹47.0 Cr: 50% of FY26 net profit of ₹93.1 Cr.

Borrowings ₹3.0 Cr at Mar 2026.

Against its own trend ?

TrendActualGap
Sales₹87.6₹104 +18.7% above
Net profit₹27.1₹32.0 +17.9% above
Detailed financials →

Hester Biosciences Limited

HESTERBIO · Pharmaceuticals · Q1 FY27 · Consolidated
M Cap
₹1,751 Cr
P/E
12.8
PEG
0.49
  • Profit +180% above its own trend
  • Operating margin expanded 274 bps YoY
  • 87% of pre-tax profit came from other income and one-off items
  • Profit grew faster than the core business (core profit -23%)
₹ CrYoYQoQ Jun 2026Mar 2026Jun 2025
Sales -8.4%-23.1% 77.010084.1
Operating profit +0.8%-36.3% 23.036.122.8
OPM % +274 bps-619 bps 29.9%36.1%27.1%
Other income —— 89.02.02.3
Net profit +460.8%+486.2% 97.016.517.3
PAT margin % +10541 bps+10945 bps 126.0%16.5%20.6%
EPS (₹) +460.7%+486.1% 114.0019.4520.33

Quality of profit

Core 13%Other income & one-offs 87%

Pre-tax profit ₹102 Cr: core business ₹13.0 Cr, other income ₹89.0 Cr.

Core profit YoY: -22.7% · reported profit +460.8%

Cash & debt

FY26 cash from operations ₹64.0 Cr: 112% of FY26 net profit of ₹57.2 Cr.

Borrowings ₹195 Cr at Mar 2026.

Against its own trend ?

TrendActualGap
Sales₹90.0₹77.0 -14.4% below
Net profit₹34.6₹97.0 +180.4% above
Detailed financials →

Jagsonpal Pharmaceuticals Limited

JAGSNPHARM · Pharmaceuticals · Q1 FY27 · Standalone
M Cap
₹1,488 Cr
P/E
32.9
PEG
2.05
  • Operating margin expanded 195 bps YoY
₹ CrYoYQoQ Jun 2026Mar 2026Jun 2025
Sales +8.5%+27.7% 82.064.275.6
Operating profit +19.7%+52.3% 17.011.214.2
OPM % +195 bps+335 bps 20.7%17.4%18.8%
Other income +6.0%-5.4% 3.03.22.8
Net profit +20.4%+48.4% 13.08.810.8
PAT margin % +157 bps+221 bps 15.9%13.6%14.3%
EPS (₹) +23.5%+52.7% 2.001.311.62

Quality of profit

Core 83%Other income & one-offs 17%

Pre-tax profit ₹18.0 Cr: core business ₹15.0 Cr, other income ₹3.0 Cr.

Core profit YoY: +29.3% · reported profit +20.4%

Cash & debt

FY26 cash from operations ₹47.0 Cr: 109% of FY26 net profit of ₹43.1 Cr.

Borrowings ₹8.0 Cr at Mar 2026.

Against its own trend ?

TrendActualGap
Sales₹79.1₹82.0 +3.6% in line
Net profit₹13.1₹13.0 -0.9% in line
Detailed financials →

Themis Medicare Limited

THEMISMED · Pharmaceuticals · Q1 FY27 · Consolidated
M Cap
₹1,008 Cr
P/E
25.0
PEG
—
  • Turnaround: profit against a loss a year ago
  • Operating margin contracted 4944 bps YoY
  • All of pre-tax profit came from other income or one-off items
  • Operating cash flow was negative in FY26 despite a profit
₹ CrYoYQoQ Jun 2026Mar 2026Jun 2025
Sales -10.8%+13.7% 87.076.597.6
Operating profit loss widenedto loss -52.03.8-10.1
OPM % -4944 bps-6468 bps -59.8%4.9%-10.3%
Other income —+815.1% 97.010.61.2
Net profit from loss+181.2% 25.08.9-14.2
PAT margin % +4331 bps+1712 bps 28.7%11.6%-14.6%
EPS (₹) from loss+175.3% 2.670.97-1.54

Quality of profit

Pre-tax profit ₹39.0 Cr: core business −₹58.0 Cr, other income ₹97.0 Cr.

Core profit YoY: loss widened

Cash & debt

FY26 cash from operations −₹3.0 Cr: -261% of FY26 net profit of ₹1.1 Cr.

Borrowings ₹100 Cr at Mar 2026.

Against its own trend ?

TrendActualGap
Sales₹85.6₹87.0 +1.7% in line
📊 Investor presentation (13 Aug) Detailed financials →

Valiant Laboratories Limited

VALIANTLAB · Pharmaceuticals · Q1 FY27 · Consolidated
M Cap
₹651 Cr
P/E
40.9
PEG
—
  • Operating margin expanded 2009 bps YoY
₹ CrYoYQoQ Jun 2026Mar 2026Jun 2025
Sales +145.6%+25.0% 11592.046.8
Operating profit —+502.9% 29.04.82.4
OPM % +2009 bps+1999 bps 25.2%5.2%5.1%
Other income +52.6%+488.2% 1.00.20.7
Net profit —— 21.01.81.8
PAT margin % +1437 bps+1635 bps 18.3%1.9%3.9%
EPS (₹) +823.8%— 3.880.320.42

Quality of profit

Core 96%Other income & one-offs 4%

Pre-tax profit ₹26.0 Cr: core business ₹25.0 Cr, other income ₹1.0 Cr.

Core profit YoY: —

Cash & debt

FY26 cash from operations −₹10.0 Cr.

Borrowings ₹46.0 Cr at Mar 2026.

Against its own trend ?

TrendActualGap
Sales₹87.6₹115 +31.3% above
Detailed financials →

Albert David Limited

ALBERTDAVD · Pharmaceuticals · Q1 FY27 · Standalone
M Cap
₹452 Cr
P/E
19.4
PEG
—
  • Operating margin expanded 2638 bps YoY
  • 78% of pre-tax profit came from other income and one-off items
₹ CrYoYQoQ Jun 2026Mar 2026Jun 2025
Sales +42.3%+17.4% 10186.071.0
Operating profit from loss+266.7% 11.03.0-11.0
OPM % +2638 bps+740 bps 10.9%3.5%-15.5%
Other income +27.3%from loss 28.0-25.022.0
Net profit +300.0%from loss 32.0-21.08.0
PAT margin % +2042 bps+5610 bps 31.7%-24.4%11.3%
EPS (₹) +303.1%from loss 56.07-37.5513.91

Quality of profit

Core 22%Other income & one-offs 78%

Pre-tax profit ₹36.0 Cr: core business ₹8.0 Cr, other income ₹28.0 Cr.

Core profit YoY: from loss · reported profit +300.0%

Cash & debt

FY26 cash from operations −₹8.0 Cr.

Borrowings ₹30.0 Cr at Mar 2026.

Against its own trend ?

TrendActualGap
Sales₹69.8₹101 +44.6% above
Detailed financials →

How to read this page

The numbers. Each card is one company's Q1 FY27 results as filed with NSE or BSE, read from the filing within hours of its release, in ₹ crore. We show the consolidated statement, or the standalone one when the consolidated figures are a copy of it or have no year-ago quarter to compare with. YoY compares with the same quarter a year earlier and QoQ with the quarter before (the previous half-year for companies that report every six months). A swing between profit and loss is described in words: a percentage across it would mislead.

Margins. Operating margin (OPM) is operating profit, before depreciation, interest and other income, as a share of sales; PAT margin is net profit as a share of sales. Their changes are in basis points (100 bps = 1 percentage point).

Quality of profit. Core profit is operating profit minus interest and depreciation: what the business itself earned before tax. The rest of pre-tax profit is other income (interest on cash, dividends, gains on investments) and exceptional or one-off items. We flag a quarter when that share is 25% or more, and when reported profit grew much faster than core profit. For banks we compare pre-provision profit with net profit, since a fall in provisions can lift profit without the business growing.

Against its own trend. We do not have analyst consensus estimates, and we do not make them up. Instead each company is measured against the path it was on: the same quarter last year, grown at the median of its last four year-on-year growth rates (held between −50% and +100%; at least two growth rates needed). Sales 5% or more above that, or net profit 10% or more above, is "above trend"; as far below is "below trend". It answers "was this quarter better or worse than the company's own recent run?", which consensus does not.

Cash and debt. Profit is an accounting figure; cash is harder to dress up. For each company we show its operating cash flow for the last financial year as a share of that year's net profit (flagged under 50%, or when it is negative despite a profit), and its borrowings at the latest balance sheet against the one six months earlier (flagged at a 25% move). Balance sheets come with the September and March results, cash-flow statements with the March results.

Price since results. The latest close against the last close before the filing (a filing after 3:30 pm counts from the next session). It is a fact about the market's reaction, not advice.

Market cap groups. Large cap is the 100 largest companies by market value and mid cap the next 150 (SEBI's ranking); below that, small cap is ₹5,000 Cr or more, micro cap ₹500 Cr or more, nano cap below.

Results calendarWho reports results today, tomorrow and this week. Strong quarterly resultsCompanies whose latest quarter showed profit up 30% or more. Live announcementsEvery NSE/BSE filing with an AI read, as it arrives. Company fundamentalsTen years of quarterly and annual financials.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI